Stockscreener 앱 받기
2.87
5.51%
0.15
시간 외 거래:
2.87
Connect Biopharma Holdings Ltd 주식(CNTB)의 최신 뉴스
Connect Biopharma (CNTB) director linked fund reports 12M-share holding - Stock Titan
Epidermolysis Bullosa Market Set for Significant Upswing During the Forecast Period (2025-2034) Amid Rising Therapeutic Advancements | DelveInsight – Company AnnouncementFT.com - Financial Times
[Form 3] Connect Biopharma Holdings Ltd Initial Statement of Beneficial Ownership - Stock Titan
Connect Biopharma (CNTB) president discloses share and option holdings - Stock Titan
Connect Biopharma (CNTB) CEO details stock option and share holdings - Stock Titan
Connect Biopharma (CNTB) SVP lists Ordinary Shares and option grants - Stock Titan
Connect Biopharma (NASDAQ: CNTB) director reports initial share and option holdings - Stock Titan
Connect Biopharma (CNTB) director lists stock option and share stakes - Stock Titan
Connect Biopharma (NASDAQ: CNTB) director reports initial stock option holdings - Stock Titan
Kleanthis Gabriel Xanthopoulos Net Worth (2026) - GuruFocus
Connect Biopharma and Bimergen Energy Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV - Pueblo Chieftain
Connect Biopharma Touts “Next-Gen Dupixent” Rademikibart, Near-Term Asthma/COPD Readouts - MarketBeat
Severe Asthma Pipeline 2026: Key Companies, MOA, ROA, and Clinical Trials Evaluation by DelveInsight | Lanier Biotherapeutics, Bio-Thera Solutions, Kinaset Therapeutics, CSPC ZhongQi Pharma - StreetInsider
Connect Biopharma Holdings Limited Sponsored ADR (NASDAQ:CNTB) Given Consensus Recommendation of "Moderate Buy" by Brokerages - MarketBeat
Simcere’s rademikibart AD study selected for AAD presentation - Investing.com
Results from Phase 3 Study of Rademikibart in Moderate-to-Severe Atopic Dermatitis to be Presented in the Late-Breaking Research Session at the 2026 American Academy of Dermatology (AAD) Annual Meeting - Bitget
Results from Phase 3 Study of Rademikibart in - GlobeNewswire
Severe eczema drug from Connect Biopharma lands late-breaking AAD slot - Stock Titan
COYA Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Connect Biopharma to Present at the Leerink Partners Global Healthcare Conference - The Manila Times
CNTB Earning Date, Earning Analysis and Earning Prediction - Intellectia AI
GNLX Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI
SELX Stock News Today | Earnings, Events & Price Alerts - Intellectia AI
CNTB Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
UCL Stock News Today | Earnings, Events & Price Alerts - Intellectia AI
CNTB Technical Analysis & Stock Price Forecast - Intellectia AI
Connect Biopharma Touts Rademikibart as Fast-Acting Option for Acute Asthma, COPD Flare-Ups at Conference - MarketBeat
BML Capital Management LLC Sells 554,058 Shares of Connect Biopharma Holdings Limited Sponsored ADR $CNTB - MarketBeat
KraneShares CSI China Internet ETF $KWEB Shares Purchased by Aurora Investment Managers LLC. - Defense World
Invesco QQQ $QQQ Stock Position Lessened by Concentrum Wealth Management - Defense World
JD.com, Inc. $JD Shares Acquired by Aurora Investment Managers LLC. - Defense World
BML Capital Management LLC Makes New Investment in ImageneBio, Inc. $IMA - Defense World
Connect Biopharma to Present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference - The Manila Times
Watch Connect Biopharma's Oppenheimer health conference talk online - Stock Titan
Wubin Pan and BioFortune Inc. disclose 10.8% stake in Connect Biopharma (CNTB) - Stock Titan
Atopic Dermatitis Market to Accelerate at a Rapid Pace by 2034 with Advancements in Biologics and JAK Inhibitors | DelveInsight - Financial Times
Connect Biopharma Holdings Limited Sponsored ADR (NASDAQ:CNTB) Given Consensus Rating of "Moderate Buy" by Analysts - MarketBeat
Connect Biopharma Holdings Limited Sponsored ADR (NASDAQ:CNTB) Given Consensus Rating of “Moderate Buy” by Analysts - Defense World
CNTB PE Ratio & Valuation, Is CNTB Overvalued - Intellectia AI
What is HC Wainwright's Forecast for CNTB FY2028 Earnings? - MarketBeat
Equities Analysts Offer Predictions for CNTB FY2030 Earnings - MarketBeat
Analysts Offer Insights on Healthcare Companies: Rani Therapeutics Holdings (RANI), Ardelyx (ARDX) and AxoGen (AXGN) - The Globe and Mail
Analysts’ Top Healthcare Picks: Context Therapeutics (CNTX), Connect Biopharma Holdings (CNTB) - The Globe and Mail
3 Promising Penny Stocks With Market Caps Up To $400M - Yahoo Finance
Connect Biopharma Holdings Limited Sponsored ADR (NASDAQ:CNTB) Receives Average Rating of "Moderate Buy" from Brokerages - MarketBeat
OPAL Fuels Inc. (NASDAQ:OPAL) Given Average Recommendation of “Reduce” by Analysts - Defense World
NVR, Inc. (NYSE:NVR) Receives Average Rating of “Moderate Buy” from Analysts - Defense World
Contrasting Joint Stock Company Kaspi.kz (NASDAQ:KSPI) & PagSeguro Digital (NYSE:PAGS) - Defense World
Connect Biopharma (NASDAQ:CNTB) Shares Down 2.7%What's Next? - MarketBeat
Connect Biopharma (NASDAQ:CNTB) Shares Down 2.7% – What’s Next? - Defense World
Plus Therapeutics Spurs After-Hours Biotech Rally; Connect Biopharma And Elutia Also Advance - Nasdaq
Analysts Offer Insights on Healthcare Companies: Regeneron (REGN), Erasca (ERAS) and Connect Biopharma Holdings (CNTB) - The Globe and Mail
Connect Biopharma Highlights New Mechanism of Action Data for Rademikibart and Outlines Priorities for 2026 - The Manila Times
Connect Biopharma Reports Significant Loss Amid Development Efforts - MSN
1.20%
0.06%
자본화:
|
볼륨(24시간):